Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma

Kim, Seung Up; Park, Jun Yong; Choi, Hye Jin; Ahn, Sang Hoon; Kim, Ja Kyung; Lee, Do-Youn; Lee, Kwang Hoon; Han, Kwang Hyub

doi:10.1007/s00432-010-0917-5

Cited by 56 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Park et al [9] showed in a study of 41 patients with unresectable HCC that repeated HAIC with high-dose 5-FU (500 mg/m 2 , days 1–3) and cisplatin (60 mg/m 2 , day 2) for 3 days significantly improved survival in patients who responded to the treatment. In this study, we selected HAIC as the method of adjuvant therapy after curative liver resection because there is growing evidence that some agents such as 5-FU and cisplatin show anticancer effects in advanced HCC when delivered into the hepatic artery [18,19,20]. …”

Section: Discussionmentioning

confidence: 99%

Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma

Kim¹,

Ahn²,

Kim³

et al. 2011

Oncology

Self Cite

View full text Add to dashboard Cite

Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma

Kim¹,

Ahn²,

Kim³

et al. 2011

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many HCC cases are in an advanced stage or unresectable at the time of diagnosis. Moreover, although unresectable advanced HCC can be treated with hepatic arterial infusion chemotherapy (HAIC) and systemic chemotherapy, the therapeutic effects are limited (1)(2)(3) and the prognosis of advanced cases of HCC is poor.…”

Section: Introductionmentioning

confidence: 99%

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Hiramine

Uto

Imamura

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Sorafenib is a kinase-targeted drug that has high efficacy for advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sorafenib is more effective than hepatic arterial infusion chemotherapy (HAIC) for HCC. Twenty patients treated with sorafenib (sorafenib group) initiated at 800 mg/day and 45 patients treated with HAIC (HAIC group) for unresectable Child-Pugh A advanced HCC were investigated retrospectively. The treatment effect was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). As a result, the overall response rate was significantly lower in the sorafenib group than in the HAIC group (P=0.03), while the disease control and survival rates did not differ between the two groups. In the sorafenib group, treatment was discontinued in 19 patients, including 12 due to side effects. In subgroups of patients treated with sorafenib, the survival rate was significantly lower in patients (n=11) administered sorafenib for <60 days compared to those (n=9) treated for ≥60 days. A shorter treatment period (<60 days) was an independent risk factor for unfavorable survival [hazard ratio (HR), 3.34; 95% confidence interval (CI), 1.45-7.66 vs. HAIC], while survival in patients treated with sorafenib for ≥60 days did not differ from those treated with HAIC (HR, 0.79; 95% CI, 0.27-2.34). In conclusion, the disease control and survival rates of patients treated with sorafenib for advanced HCC were comparable to such rates in patients treated with HAIC.However, the prognosis was poor when long-term sorafenib treatment was not possible due to side effects, demonstrating the importance of patient selection for sorafenib treatment.

show abstract

“…In addition to fluoropyrimidine (mostly 5-fluorouracil) monotherapy 29 , the combination of 5-fluorouracil and cisplatin has been the most commonly used HAI regimen in HCC (ref. 8,14,16,17,20 ). The efficacy of HAI of 5-fluorouracil/cisplatin combination seems to be higher than HAI of 5-fluorouracil alone 17 .…”

Section: Discussionmentioning

confidence: 99%

“…While chemoembolization, another liver-directed procedure targeting the vasculature, is a standard method in the management of patients with inoperable HCC based on the results of prospective trials indicating survival benefit 7 , the utilization of HAI in this setting is less frequent. Numerous studies on HAI in HCC have been reported from East Asia, especially from Japan [8][9][10][11][12][13][14][15][16][17][18][19][20] , but the experience with this approach in the Caucasian population of Western countries is very limited 21,22 . The use of HAI is currently not recommended in therapeutic guidelines, but this approach has been used in the past.…”

Section: Introductionmentioning

confidence: 99%

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Melichar¹,

Dvořák²,

Ferko³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aim. The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma. Methods. A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007. Results. Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure or because only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI. Conclusion. The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.

show abstract

Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma

Abstract: Repetitive HAIC seems well-tolerated and effective in treating advanced HCC, with more therapeutic benefit when treated with cisplatin plus 5-fluorouracil. Future randomized comparative studies are warranted for its efficacy.

Cited by 56 publications

References 27 publications

Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma

Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma

Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Contact Info

Product

Resources

About